Cardiologist William Hiatt, MD (University of Colorado School of Medicine) has a problem with the Food and Drug Administration’s proposal to require cardiovascular outcomes studies for all weight loss drugs, even in the absence of a clear signal of CV risk.
“If you want to impose this requirement on a drug with no signals, I think you ought to impose it...